Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

FHTX : 8.85 (-0.11%)
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

FHTX : 8.85 (-0.11%)
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

FHTX : 8.85 (-0.11%)
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

/CNW/ -- USA News Group – Optimism is on the rise in fight against cancer, as researchers are making progress across the field of oncology. Helping to spur on...

ONCY : 1.0500 (+1.94%)
FHTX : 8.85 (-0.11%)
NRIX : 27.15 (+0.44%)
INCY : 80.46 (-0.02%)
ONC.TO : 1.47 (-5.16%)
REGN : 804.33 (-2.03%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 29.63 (-0.87%)
FHTX : 8.85 (-0.11%)
MRNA : 42.21 (+0.17%)
OMGA : 1.0700 (unch)
SANA : 2.67 (+0.38%)
MCRB : 0.6100 (+3.35%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 29.63 (-0.87%)
FHTX : 8.85 (-0.11%)
MRNA : 42.21 (+0.17%)
OMGA : 1.0700 (unch)
SANA : 2.67 (+0.38%)
MCRB : 0.6100 (+3.35%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 29.63 (-0.87%)
FHTX : 8.85 (-0.11%)
MRNA : 42.21 (+0.17%)
OMGA : 1.0700 (unch)
SANA : 2.67 (+0.38%)
MCRB : 0.6100 (+3.35%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 29.63 (-0.87%)
FHTX : 8.85 (-0.11%)
MRNA : 42.21 (+0.17%)
OMGA : 1.0700 (unch)
SANA : 2.67 (+0.38%)
MCRB : 0.6100 (+3.35%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 29.63 (-0.87%)
FHTX : 8.85 (-0.11%)
MRNA : 42.21 (+0.17%)
OMGA : 1.0700 (unch)
SANA : 2.67 (+0.38%)
MCRB : 0.6100 (+3.35%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 29.63 (-0.87%)
FHTX : 8.85 (-0.11%)
MRNA : 42.21 (+0.17%)
OMGA : 1.0700 (unch)
SANA : 2.67 (+0.38%)
MCRB : 0.6100 (+3.35%)

Barchart Exclusives

META 2025 Forecast: Does a Trump-Musk Combo Spell Trouble for Meta Stock?
Meta is the second best-performing Magnificent 7 stock in 2024 for the second consecutive year. What's the forecast for the stock as Trump returns to the White House next year, with Mark Zuckerberg rival Elon Musk as his key lieutenant? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar